Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksORPH.L Share News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Cyanconnode, Rosslyn Data rise on contract wins

Mon, 22nd Aug 2022 11:03

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Cyanconnode Holdings PLC, up 29% at 19.00 pence, 12-month range 11.00p-29.85p. The narrowband radio frequency smart mesh networks firm says Indian subsidiary has received its largest-ever order. CyanConnode India Pvt Ltd has received an order from Genus Power Infrastructures Ltd for one million Omnimesh modules, together with advanced metering infrastructure, standards-based hardware, Omnimesh head-end software, perpetual license and a support and maintenance contract. The support and maintenance contract runs for eight years, starting upon completion of the installation phase.

----------

Rosslyn Data Technologies PLC, up 12% at 2.36p, 12-month range 1.50p-5.98p. The data management and analytics service provider wins first enterprise customer through partnership with indirect procurement service provider Chain IQ Group AG. Says initial contract is "of relatively small monetary value" but expects further contracts to come from partnership. Chief Executive Paul Watts says deal highlights value of partnership with Chain IQ.

----------

Open Orphan PLC, up 5.9% at 11.91p, 12-month range 10.00p-27.75p. The pharmaceutical services firm says subsidiary hVIVO Ltd has won a GBP10.4 million contract. Open Orphan says the contract has been signed with an "existing top five global pharmaceutical client". This is the third human challenge contract signed with the client, it adds.

----------

AIM - LOSERS

----------

Artemis Resources Ltd, down 11% at 2.05p, 12-month range 1.44p-5.00p. The miner says no significant nickel or copper results are found in laboratory analyses of samples from the first drill hole at the Osborne nickel prospect. Further, in a separate statement regarding its Greater Carlow project, holes ARC395 and ARC396 "did not return any significant mineralisation, in line with the offset of the lodes already discovered by holes ARC403 and ARC404," the Perth-based miner with gold, copper and cobalt projects in Australia adds.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2020 10:51

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Open Orphan Takeover Of hVIVO Now Wholly Unconditional

Read more
16 Jan 2020 18:15

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Open Orphan Readmitted To AIM Following Reverse Takeover Of hVIVO

Read more
14 Jan 2020 16:10

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Open Orphan To Mount Compulsory Buyout To Get hVIVO Deal Over Line

Read more
6 Jan 2020 17:29

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

UPDATE: Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 11:49

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Open Orphan To Relist On AIM Following hVIVO All-Share Merger

Read more
6 Jan 2020 10:55

Open Orphan inks three-year contract with mystery European firm

(Sharecast News) - Drug consulting services platform Open Orphan has won a new three-year contract with an unnamed German pharmaceutical company.

Read more
31 Dec 2019 09:46

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Open Orphan Meets Acceptance Condition For Merger With hVIVO

Read more
31 Dec 2019 06:31

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
18 Dec 2019 12:54

Open Orphan signs deal with US biopharmaceutical firm SFA

(Sharecast News) - Europe-focussed rare and orphan drug consulting service provider Open Orphan announced the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, on Wednesday.

Read more
18 Dec 2019 12:29

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Open Orphan Unit To Assist SFA Therapeutics In Filing Drug Application

Read more
9 Dec 2019 14:36

Open Orphan agrees acquisition of hVIVO at 34% premium

(Sharecast News) - Open Orphan, the rare and orphan drug services company, has agreed the takeover of hVIVO by means of an all-share reverse take-over at a 33.8% premium.

Read more
9 Dec 2019 11:23

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

AIM-Listed Firms Open Orphan And hVIVO Set For Tie-Up

Read more
25 Nov 2019 14:57

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Open Orphan Signs Five Companies For Genomic Health DataBANK Platform

Read more
18 Nov 2019 10:35

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Open Orphan Teams With Carna For Human Clinical Pharmacology Trial

Read more
18 Nov 2019 09:58

Open Orphan signs pharmacology trial contract with Carna

(Sharecast News) - Rare and orphan drug consulting services provider Open Orphan announced the signing of a contract with Carna Bioscience for a first-in-human clinical pharmacology trial, it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.